Overview

• Analysis cited by the Mirror shows June prescribing ranged from 1,250 GLP-1 prescriptions per 10,000 obese adults in North Lincolnshire to 265 in North Tyneside.
• Patients unable to access NHS treatment are paying private pharmacies up to £200 a month, with areas such as southeast London and Northumberland described as deserts for the jabs.
• The NHS says it is supporting a phased rollout of tirzepatide for eligible patients with NICE-aligned guidance and March 2025 funding for integrated care boards to build services.
• Experts including Professors Nick Finer and Nerys Astbury warn that supply, infrastructure and GP capacity remain inadequate to meet rising demand.
• The Daily Mail reports that generic semaglutide could lower private costs by as much as 60–90 percent from early 2026 as foreign patents lapse, with industry figures warning about risks from unregulated grey-market imports.